http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
성혜란(Hyeran Sung),김지연(Jee Youn Kim),박민경(Min Gyeong Park),김일회(Il-Hoi Kim),이동욱(Dong Wook Lee),한상배(Sang-Bae Han),이종길(Chong-Kil Lee),송석길(Sukgil Song) 대한약학회 2010 약학회지 Vol.54 No.3
Colorectal cancer is one of the most common alimentary malignancies. In this study, the antitumor activity of activated human natural killer (NK) cells against human colorectal cancer was evaluated in vivo. Human NK cells are the key contributors of innate immune response and the effective functions of these cells are enhanced by cytokines. Human peripheral blood mononuclear cells (PBMC) were cultured with interleukin-2 (IL-2)-containing medium for 14 days and resulted in enriched NK cell population. The resulting populations of the cells comprised 7% CD3+CD4+ cells, 25% CD3+CD8+ cells, 13% CD3-CD8+ cells, 4% CD3+CD16/CD56+ cells, 39% CD3+CD16/CD56- cells, and 52% CD3-CD16/CD56+ cells. Tumor necrosis factor alpha (TNF-α), interferon gamma (IFN-γ), IL-2, IL-4, and IL-5 transcripts of the activated NK cells were confirmed by RT-PCR. In addition, activated NK cells at doses of 2.5, 5 and 10 million cells per mouse inhibited 10%, 34% and 47% of SW620-induced tumor growth in nude mouse xenograft assays, respectively. This study suggests that NK cell-based immunotherapy may be used as an adoptive immunotherapy for colorectal cancer patients.
박민경(Min Gyeong Park),한상배(Sang-Bae Han),김지연(Jee Youn Kim),박지성(Ji-sung Park),성혜란(Hyeran Sung),윤병규(Byung Kui Yun),송석길(Sukgil Song),이종길(Chong-Kil Lee) 大韓藥學會 2011 약학회지 Vol.55 No.3
Human NK cells, identified 30 years ago based on their ability to spontaneously kill tumor cells, constitute a subset of lymphocytes, which play an important role in the first line of immune defense and the effective function of these cells are enhanced by cytokines. Lung carcinoma has been one of the most commonly diagonosed cancer as well as the leading cause of cancer death in male. Here we provide the evidence that human natural killer cells has inhibitory effects on tumor growth of human lung cancer cell NCI-H460 (non-small cell lung cancer). Enriched NK cell population was obtained by 2 weeks cultivation in interleukin-2(IL-2)-containing medium. The resulting population comprised 26% CD3+ cells, 9% CD3+CD4+ cells, 16% CD3+CD8+ cells, 76% CD56+ cells, 6% CD3+CD56+ cells and 70% CD3-CD56+ cells. Activated NK cells at doese of 2.5, 5, and 10 million cells per mouse inhibited 2%, 12% and 45% of NCI-H460-induced tumor growth in nude mouse xenograft assays, repectively. This result suggests that NK cell-based immunotherapy may be used as an adoptive immunotherapy for lung cancer patients.